Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Evaluation of Anti-Tumor Activity and Impact on T Cell Activation of Glofitamab in Combination with Gemcitabine and Oxaliplatin (Glofit-GemOx)

Marina Bacac, Johannes Sam, Won Seog Kim, Gareth P. Gregory, Matthew Ku, Sylvia Herter, Christian Klein, Pablo Umana, Stephen Simko, Victor Orellana-Noia, Linda Lundberg, Alessia Bottos

Blood (2024) 144 (Supplement 1): 2990.

https://doi.org/10.1182/blood-2024-200753

Published: 2024

Journal Articles

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

Blood blood.2024025987.

https://doi.org/10.1182/blood.2024025987

Published: 2024

Includes: Supplemental data

Journal Articles

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy

Blood (2024) 143 (21): 2152–2165.

https://doi.org/10.1182/blood.2023023381

Published: 2024

Includes: Supplemental data

Journal Articles

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Blood (2023) 142 (Supplement 1): 3017.

https://doi.org/10.1182/blood-2023-173677

Published: 2023

Journal Articles

Early Intervention with Celmods, but Not Imids, Prevents Relapse to Forimtamig Driven By GPRC5D-Negative Myeloma Cells

Jan Eckmann, Carina Hage, Lechner Stefanie, Christa Bayer, Christian Klein, Pablo Umana

Blood (2023) 142 (Supplement 1): 4659.

https://doi.org/10.1182/blood-2023-174253

Published: 2023

Journal Articles

Fine Tuning Bispecific Activity in CLL: Harmonizing a CD19/20-T Cell Bispecific with a CD28 or 4-1BBL Costimulatory Bispecific

Giulia Petra Rappa, Monika Sponheimer, Gerulf Hänel, Anne-Sophie Neumann, Nora Philipp, Koorosh Korfi, Sylvia Herter, Johannes Sam, Franz Schuler, Christian Klein, Marina Bacac, Pablo Umana, Marion Subklewe

Blood (2023) 142 (Supplement 1): 2058.

https://doi.org/10.1182/blood-2023-180785

Published: 2023

Journal Articles

Molecular Mechanisms Underlying Response and Resistance to Glofitamab

Sina Nassiri, Stephan Schmeing, Gabrielle Leclercq, Sylvia Herter, Llucia Alberti Servera, Tamara Hüsser, Emilio Yángüez, Diana Dunshee, Koorosh Korfi, Pablo Umana, Ann-Marie E. Bröske, Alessia Bottos, Marina Bacac

Blood (2023) 142 (Supplement 1): 1619.

https://doi.org/10.1182/blood-2023-179776

Published: 2023

Journal Articles

RG6333 (CD19-CD28), a CD19-Targeted Affinity-Optimized CD28 Bispecific Antibody, Enhances and Prolongs the Anti-Tumor Activity of Glofitamab (CD20-TCB) in Preclinical Models

Blood (2022) 140 (Supplement 1): 3142–3143.

https://doi.org/10.1182/blood-2022-159941

Published: 2022

Journal Articles

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Blood (2022) 140 (Supplement 1): 10137–10139.

https://doi.org/10.1182/blood-2022-158146

Published: 2022

Journal Articles

RG6234: A Novel 2:1 GPRC5D T Cell Bispecific Antibody Exhibits Best in Class Potential for the Treatment of Multiple Myeloma As a Monotherapy and in Combination

Blood (2022) 140 (Supplement 1): 2091–2092.

https://doi.org/10.1182/blood-2022-157485

Published: 2022

Journal Articles

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody

Blood (2021) 138 (25): 2655–2669.

https://doi.org/10.1182/blood.2020010477

Published: 2021

Includes: Supplemental data

Journal Articles

Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist

Gerulf Hänel, Anne-Sophie Neumann, Vesna Pulko, Christina Claus, Alexandra Leutbecher, Anetta Marcinek, Nora Zieger, Veit L Buecklein, Pablo Umana, Christian Klein, Marion Subklewe

Blood (2021) 138 (Supplement 1): 1178.

https://doi.org/10.1182/blood-2021-146762

Published: 2021

Journal Articles

RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies

Sylvia Herter, PhD, Johannes Sam, PhD, Claudia Ferrara Koller, PhD, Sarah Diggelmann, Esther Bommer, Anne Schönle, Christina Claus, PhD, Marina Bacac, PhD, Christian Klein, PhD, Pablo Umana, PhD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-134782

Published: 2020

Journal Articles

Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide

Blood (2019) 134 (Supplement_1): 4450.

https://doi.org/10.1182/blood-2019-130121

Published: 2019

Journal Articles

CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies

Marina Bacac, PhD, Pablo Umaña, PhD, Sylvia Herter, PhD, Sara Colombetti, PhD, Johannes Sam, PhD, Marine Le Clech, Anne Freimoser-Grundschober, PhD, Marine Richard, Valeria Nicolini, PhD, Christian Gerdes, PhD, Laurent Lariviere, PhD, Christiane Neumann, PhD, Christian Klein, PhD

Blood (2016) 128 (22): 1836.

https://doi.org/10.1182/blood.V128.22.1836.1836

Published: 2016

Journal Articles

The Triple Combination of the CD20 Antibody Obinutuzumab with the Bcl-2 Inhibitor Venetoclax (GDC-199) and the MDM2 Inhibitor Idasanutlin Results in Superior Efficacy and Long Term Response in Wildtype p53 NHL Tumor Models

Frank Herting, PhD, Thomas Friess, PhD, Pablo Umaña, PhD, Middleton Steven, PhD, Christian Klein, PhD

Blood (2016) 128 (22): 4178.

https://doi.org/10.1182/blood.V128.22.4178.4178

Published: 2016

Journal Articles

A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys

Blood (2015) 126 (23): 2998.

https://doi.org/10.1182/blood.V126.23.2998.2998

Published: 2015

Journal Articles

The PI3K Delta Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function and B Cell Depletion Mediated By Obinutuzumab (GA101) and Rituximab

Sylvia Herter, PhD, Adam Palazzo, Marina Bacac, PhD, Laura Grosmaire, MS, Christian Frey, PhD, Stefan Pflanz, PhD, Jia Liu, PhD, Stacey Tannheimer, PhD, Pablo Umana, PhD, Christian Klein, PhD, Christophe Queva, PhD

Blood (2014) 124 (21): 3342.

https://doi.org/10.1182/blood.V124.21.3342.3342

Published: 2014

Journal Articles

Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo

Sylvia Herter, PhD, Idit Sagiv-Barfi, PhD, Cariad Chester, Mohith Sadaram, BS, Jonathan Hebb, MD, Debra K Czerwinski, Narendiran Rajasekaran, PhDMSc, Marina Bacac, PhD, Pablo Umana, PhD, Ron Levy, MD, Christian Klein, PhD, Holbrook E Kohrt, MD PhD

Blood (2014) 124 (21): 1765.

https://doi.org/10.1182/blood.V124.21.1765.1765

Published: 2014

Journal Articles

Obinutuzumab (GA101) More Potently Engages Phagocytic-Lineage Cells Resulting In Enhanced Monocyte and Macrophage Activity When Compared To Rituximab and Ofatumumab

Sylvia Herter, PhD, Christian Klein, PhD, Pablo Umana, PhD, Marina Bacac

Blood (2013) 122 (21): 5136.

https://doi.org/10.1182/blood.V122.21.5136.5136

Published: 2013

NARROW

Evaluation of Anti-Tumor Activity and Impact on T Cell Activation of Glofitamab in Combination with Gemcitabine and Oxaliplatin (Glofit-GemOx)

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy

Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial

Early Intervention with Celmods, but Not Imids, Prevents Relapse to Forimtamig Driven By GPRC5D-Negative Myeloma Cells

Fine Tuning Bispecific Activity in CLL: Harmonizing a CD19/20-T Cell Bispecific with a CD28 or 4-1BBL Costimulatory Bispecific

Molecular Mechanisms Underlying Response and Resistance to Glofitamab

RG6333 (CD19-CD28), a CD19-Targeted Affinity-Optimized CD28 Bispecific Antibody, Enhances and Prolongs the Anti-Tumor Activity of Glofitamab (CD20-TCB) in Preclinical Models

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

RG6234: A Novel 2:1 GPRC5D T Cell Bispecific Antibody Exhibits Best in Class Potential for the Treatment of Multiple Myeloma As a Monotherapy and in Combination

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody

Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist

RG6076 (CD19-4-1BBL): CD19-Targeted 4-1BB Ligand Combination with Glofitamab As an Off-the-Shelf, Enhanced T-Cell Redirection Therapy for B-Cell Malignancies

Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide

CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies

The Triple Combination of the CD20 Antibody Obinutuzumab with the Bcl-2 Inhibitor Venetoclax (GDC-199) and the MDM2 Inhibitor Idasanutlin Results in Superior Efficacy and Long Term Response in Wildtype p53 NHL Tumor Models

A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys

The PI3K Delta Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function and B Cell Depletion Mediated By Obinutuzumab (GA101) and Rituximab

Obinutuzumab (GA101) Is Less Prone to Antagonism of Immune Effector Function By Ibrutinib Than Rituximab in Vitro and in Vivo

Obinutuzumab (GA101) More Potently Engages Phagocytic-Lineage Cells Resulting In Enhanced Monocyte and Macrophage Activity When Compared To Rituximab and Ofatumumab

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only